ViiV/Janssen's Double-Edged SWORD: Four Drugs Good, Two Drugs Better?

Data from ViiV Healthcare and Janssen's SWORD study point the way to a two-drug future in HIV for Tivicay/Edurant, but will doctors want to rock the boat, especially with Gilead's bictegravir impressing in Phase II?